Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BIIB074 in Healthy Japanese and Caucasian Subjects
NCT02831517Phase 1Completed
- Sponsor
- Biogen
- Start
- Aug 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vixotrigine in trigeminal neuralgia (TN) (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration, Time to Reach Cmax and 13 more. Started Aug 2016; status: completed.
02
Drugs
vixotrigine
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT02831517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831517.